PEIJIA-B(09996.HK): First Patient Implant Completed in US Early Feasibility Study of GeminiOne® TEER System
NewTimeSpace News: Peijia Medical Limited (09996.HK) announced the successful completion of the first patient implant in the US FDA early feasibility study of the GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) System.The procedure was performed by Professor Saibal Kar, Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles.
NewTimeSpace News: Peijia Medical Limited (09996.HK) issued a voluntary announcement on April 9, 2026, providing an update on the US early feasibility study of the GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) System.
The first patient implant in the US FDA early feasibility study of the GeminiOne® TEER System has been successfully completed.
The procedure was performed by Professor Saibal Kar, Director of Interventional Structural Heart Disease and Clinical Research at Los Robles Regional Medical Center (affiliated with HCA Healthcare) and Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles.
The Company cautions that it may ultimately be unable to successfully develop and commercialize the GeminiOne® TEER System.
Shareholders and potential investors should exercise caution when dealing in the Company’s shares.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
